Asymmetrex is on the path to success.
Boston, MA (PRWEB) November 17, 2016
“Asymmetrex is on the path to success.” James Sherley, director of Asymmetrex, confidently spoke these words when he recounted the business development progress of the company that he founded three years earlier. Sherley was speaking at the 1st Annual Preclinical Development Operations Summit, organized by Arena International Events Group, on November 15-16, in Boston.
Developing more effective collaboration and partnership between contract research organizations (CRO) and their pharmaceutical company and cell therapy company sponsors was the major focus of the Summit. However, in addition to attendance by heads of drug development and cell therapy development from well-established companies, the Summit also included executives from new pharmaceutical and CRO start-ups. Asymmetrex, having recently launched a new contract service that provides, for the first time, tissue stem cell counting for both support of drug development and stem cell therapeutics, was invited to present. Director Sherley reviewed the company’s current business strategy and its longer-term vision of leveraging the new CRO business towards future success as an adult tissue stem cell biomanufacturing company.
Fifteen minutes before Sherley began his presentation on the first day of the Summit, at 12 pm EDT, the clinical trials news site of Arena International published a new perspective from him on the importance of private stem cell treatment clinics to the future of stem cell biomedicine. The article considers that these clinics have been generally mischaracterized regarding their motivation and their research merit. Sherley emphasizes that their presently unregulated stem cell treatments are a part of the long tradition of routine medical practice also serving as a source of scientific discovery and medical innovation. The article makes recommendations for improvements in current treatment practices in private clinics that would increase the quality of care and the utility of knowledge obtained to accelerate progress in stem cell medicine.
Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Currently, Asymmetrex’s focus is employing its technological advantages to develop and market facile methods for monitoring adult stem cell number and function in stem cell transplantation treatments and in pre-clinical assays for drug safety.